Scott Alexander drafts a letter to the FDA arguing against their decision to halt 23andMe's genetic testing services, highlighting the benefits and addressing the FDA's concerns. Longer summary

Scott Alexander writes a letter to the FDA expressing concern about their decision to halt 23andMe's genetic testing services. He argues that personal genomics services like 23andMe provide valuable and affordable genetic information to patients and doctors, raise awareness about genetics, and contribute to genetic research. Scott counters the FDA's concerns about false positives, test validation, and patient self-management, suggesting that these issues are either manageable or apply to many other medical tests and information sources. He urges the FDA to work with 23andMe to ensure their service returns to the market quickly. Shorter summary